Evidence map›Paper›PMID 21515327›Full record

ArticleVaccine2011

Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Andrés Obregón-Henao, Crystal Shanley, María Verónica Bianco, Angel A Cataldi, Randall J Basaraba, Ian M Orme, Fabiana Bigi

Abstract read
In one paragraph

Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. The chosen few:Frontiers in immunology · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Andrés Obregón-HenaoDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. aobregon@colostate.edu
Crystal Shanley
María Verónica Bianco
Angel A Cataldi
Randall J Basaraba
Ian M Orme
Fabiana Bigi
Colorado State University · USNational Agricultural Technology Institute · AR

Funding

Response Therapies for MDR-TBU01AI070456 · NIAID · COLORADO STATE UNIVERSITY · PI ORME, IAN M · 2006 to 2010
$6.4M
NIAID NIH HHS AI-070456NIAID NIH HHS U01 AI070456
6 · The paper itself

Abstract

The limited efficacy of the BCG vaccine for tuberculosis, coupled with emerging information suggesting that it is poorly protective against newly emerging strains of Mycobacterium tuberculosis such as the W-Beijing isolates, makes it paramount to search for more potent alternatives. One such class of candidates is attenuated mutants derived from M. tuberculosis itself. We demonstrate here, in an initial short term assay, that mutants derived from disruption of the mce genes of the bacillus were highly protective in guinea pigs exposed by low dose aerosol infection with the virulent W-Beijing isolate SA161. This protection was demonstrated by a significant reduction in the numbers of bacilli harvested from the lungs, and dramatic improvements in lung histopathology.

Indexed as

MutationAnimalsBacterial LoadBacterial ProteinsFemaleGuinea PigsHumansLungMycobacterium tuberculosisOperonSpecific Pathogen-Free OrganismsTreatment OutcomeTuberculosis, PulmonaryTuberculosis VaccinesVaccinationVaccines, AttenuatedBacterial ProteinsTuberculosis VaccinesVaccines, Attenuated

Identifiers

PMID21515327
PMCPMC3175756
OpenAlexW1972466102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.